Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T22285
(Former ID: TTDS00123)
|
|||||
| Target Name |
Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
|
|||||
| Synonyms |
NR2A; NMDA receptor NR2A; N-methyl D-aspartate receptor subtype 2A; HNR2A; Glutamate receptor ionotropic, NMDA 2A; Glutamate [NMDA] receptor subunit epsilon-1; GluN2A
|
|||||
| Gene Name |
GRIN2A
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Nutritional deficiency [ICD-11: 5B50-5B71] | |||||
| Function |
Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition; channels containing GRIN1 and GRIN2A have higher sensitivity to glutamate and faster kinetics than channels formed by GRIN1 and GRIN2B. Contributes to the slow phase of excitatory postsynaptic current, long-term synaptic potentiation, and learning. Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium.
Click to Show/Hide
|
|||||
| BioChemical Class |
Glutamate-gated ion channel
|
|||||
| UniProt ID | ||||||
| Sequence |
MGRVGYWTLLVLPALLVWRGPAPSAAAEKGPPALNIAVMLGHSHDVTERELRTLWGPEQA
AGLPLDVNVVALLMNRTDPKSLITHVCDLMSGARIHGLVFGDDTDQEAVAQMLDFISSHT FVPILGIHGGASMIMADKDPTSTFFQFGASIQQQATVMLKIMQDYDWHVFSLVTTIFPGY REFISFVKTTVDNSFVGWDMQNVITLDTSFEDAKTQVQLKKIHSSVILLYCSKDEAVLIL SEARSLGLTGYDFFWIVPSLVSGNTELIPKEFPSGLISVSYDDWDYSLEARVRDGIGILT TAASSMLEKFSYIPEAKASCYGQMERPEVPMHTLHPFMVNVTWDGKDLSFTEEGYQVHPR LVVIVLNKDREWEKVGKWENHTLSLRHAVWPRYKSFSDCEPDDNHLSIVTLEEAPFVIVE DIDPLTETCVRNTVPCRKFVKINNSTNEGMNVKKCCKGFCIDILKKLSRTVKFTYDLYLV TNGKHGKKVNNVWNGMIGEVVYQRAVMAVGSLTINEERSEVVDFSVPFVETGISVMVSRS NGTVSPSAFLEPFSASVWVMMFVMLLIVSAIAVFVFEYFSPVGYNRNLAKGKAPHGPSFT IGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEFVD QVTGLSDKKFQRPHDYSPPFRFGTVPNGSTERNIRNNYPYMHQYMTKFNQKGVEDALVSL KTGKLDAFIYDAAVLNYKAGRDEGCKLVTIGSGYIFATTGYGIALQKGSPWKRQIDLALL QFVGDGEMEELETLWLTGICHNEKNEVMSSQLDIDNMAGVFYMLAAAMALSLITFIWEHL FYWKLRFCFTGVCSDRPGLLFSISRGIYSCIHGVHIEEKKKSPDFNLTGSQSNMLKLLRS AKNISSMSNMNSSRMDSPKRAADFIQRGSLIMDMVSDKGNLMYSDNRSFQGKESIFGDNM NELQTFVANRQKDNLNNYVFQGQHPLTLNESNPNTVEVAVSTESKANSRPRQLWKKSVDS IRQDSLSQNPVSQRDEATAENRTHSLKSPRYLPEEMAHSDISETSNRATCHREPDNSKNH KTKDNFKRSVASKYPKDCSEVERTYLKTKSSSPRDKIYTIDGEKEPGFHLDPPQFVENVT LPENVDFPDPYQDPSENFRKGDSTLPMNRNPLHNEEGLSNNDQYKLYSKHFTLKDKGSPH SETSERYRQNSTHCRSCLSNMPTYSGHFTMRSPFKCDACLRMGNLYDIDEDQMLQETGNP ATGEQVYQQDWAQNNALQLQKNKLRISRQHSYDNIVDKPRELDLSRPSRSISLKDRERLL EGNFYGSLFSVPSSKLSGKKSSLFPQGLEDSKRSKSLLPDHTSDNPFLHSHRDDQRLVIG RCPSDPYKHSLPSQAVNDSYLRSSLRSTASYCSRDSRGHNDVYISEHVMPYAANKNNMYS TPRVLNSCSNRRVYKKMPSIESDV Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
| HIT2.0 ID | T74SS7 | |||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Glycine | Drug Info | Approved | Malnutrition | [2], [3] | |
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | NBQX | Drug Info | Phase 1 | Neurological disorder | [4] | |
| Discontinued Drug(s) | [+] 6 Discontinued Drugs | + | ||||
| 1 | YM-90K | Drug Info | Discontinued in Phase 2 | Convulsion | [5] | |
| 2 | DIZOCILPINE | Drug Info | Terminated | Cerebrovascular ischaemia | [6], [7] | |
| 3 | L-689560 | Drug Info | Terminated | Neurodegenerative disorder | [8], [9] | |
| 4 | L-698532 | Drug Info | Terminated | Neurological disorder | [10] | |
| 5 | L-698544 | Drug Info | Terminated | Alzheimer disease | [11] | |
| 6 | L-701324 | Drug Info | Terminated | Cerebrovascular ischaemia | [12], [13], [14] | |
| Mode of Action | [+] 5 Modes of Action | + | ||||
| Antagonist | [+] 14 Antagonist drugs | + | ||||
| 1 | Glycine | Drug Info | [1] | |||
| 2 | L-689560 | Drug Info | [19] | |||
| 3 | CGP61594 | Drug Info | [19] | |||
| 4 | d-AP5 | Drug Info | [19] | |||
| 5 | d-CCPene | Drug Info | [19] | |||
| 6 | LY233053 | Drug Info | [19] | |||
| 7 | MDL 100,453 | Drug Info | [40] | |||
| 8 | NVP-AAM077 | Drug Info | [42] | |||
| 9 | Tenocyclidine | Drug Info | [45] | |||
| 10 | UBP141 | Drug Info | [25] | |||
| 11 | [3H]CGP39653 | Drug Info | [19] | |||
| 12 | [3H]CGS19755 | Drug Info | [19] | |||
| 13 | [3H]CPP | Drug Info | [19] | |||
| 14 | [3H]MDL105519 | Drug Info | [19] | |||
| Inhibitor | [+] 67 Inhibitor drugs | + | ||||
| 1 | NBQX | Drug Info | [15] | |||
| 2 | YM-90K | Drug Info | [16] | |||
| 3 | DIZOCILPINE | Drug Info | [17] | |||
| 4 | L-687414 | Drug Info | [18] | |||
| 5 | L-695902 | Drug Info | [18] | |||
| 6 | L-698532 | Drug Info | [20] | |||
| 7 | L-698544 | Drug Info | [18] | |||
| 8 | L-701324 | Drug Info | [20] | |||
| 9 | MDL-105519 | Drug Info | [21] | |||
| 10 | RPR-104632 | Drug Info | [22] | |||
| 11 | SPERMINE | Drug Info | [23] | |||
| 12 | (D)-Ala-Pro-Glu | Drug Info | [24] | |||
| 13 | (R)-2-Amino-5-phosphono-pentanoic acid | Drug Info | [25] | |||
| 14 | (R)-2-Amino-7-phosphono-heptanoic acid | Drug Info | [25] | |||
| 15 | 1,3-ditolylguanidine | Drug Info | [26] | |||
| 16 | 2-Methylamino-succinic acid(NMDA) | Drug Info | [19], [27] | |||
| 17 | 3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one | Drug Info | [18] | |||
| 18 | 3-Hydroxy-1H-benzo[b]azepine-2,5-dione | Drug Info | [28] | |||
| 19 | 3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione | Drug Info | [28] | |||
| 20 | 3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione | Drug Info | [28] | |||
| 21 | 3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione | Drug Info | [28] | |||
| 22 | 3-phenyl-4-hydroxyquinolin-2(1H)-one | Drug Info | [20] | |||
| 23 | 4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one | Drug Info | [29] | |||
| 24 | 4,6-Dichloro-1H-indole-2-carboxylic acid | Drug Info | [30] | |||
| 25 | 4-Bromo-3-hydroxy-1H-quinolin-2-one | Drug Info | [29] | |||
| 26 | 4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one | Drug Info | [29] | |||
| 27 | 4-Chloro-3-hydroxy-1H-quinolin-2-one | Drug Info | [29] | |||
| 28 | 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one | Drug Info | [20] | |||
| 29 | 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol | Drug Info | [31] | |||
| 30 | 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol | Drug Info | [31] | |||
| 31 | 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol | Drug Info | [31] | |||
| 32 | 4-[3-(4-Phenyl-butylamino)-propyl]-phenol | Drug Info | [31] | |||
| 33 | 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol | Drug Info | [31] | |||
| 34 | 5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione | Drug Info | [32] | |||
| 35 | 5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one | Drug Info | [18] | |||
| 36 | 5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione | Drug Info | [18] | |||
| 37 | 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione | Drug Info | [32] | |||
| 38 | 6-Chloro-1,4-dihydro-quinoxaline-2,3-dione | Drug Info | [33] | |||
| 39 | 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione | Drug Info | [33] | |||
| 40 | 7-chloro-3-hydroxyquinazoline-2,4-dione | Drug Info | [34] | |||
| 41 | 8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione | Drug Info | [28] | |||
| 42 | 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione | Drug Info | [28] | |||
| 43 | 8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione | Drug Info | [28] | |||
| 44 | 8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione | Drug Info | [28] | |||
| 45 | Ala-Pro-Glu | Drug Info | [24] | |||
| 46 | AP-7 | Drug Info | [35] | |||
| 47 | Benzyl 4-aminobutyl(3-aminopropyl)carbamate | Drug Info | [36] | |||
| 48 | Conantokin-R | Drug Info | [37] | |||
| 49 | DNQX | Drug Info | [38] | |||
| 50 | Gly-Amp-Glu | Drug Info | [24] | |||
| 51 | Gly-b7Pro-Glu | Drug Info | [24] | |||
| 52 | Gly-Hyp-Glu | Drug Info | [24] | |||
| 53 | Gly-Pip-Glu | Drug Info | [24] | |||
| 54 | H-Gly-D-dmP-Glu-OH | Drug Info | [39] | |||
| 55 | H-Gly-dmP-Glu-OH | Drug Info | [39] | |||
| 56 | N,N'-Bis-(4-butoxy-phenyl)-guanidine | Drug Info | [26] | |||
| 57 | N,N'-Bis-(4-butyl-phenyl)-guanidine | Drug Info | [26] | |||
| 58 | N,N'-Bis-(4-ethyl-phenyl)-guanidine | Drug Info | [26] | |||
| 59 | N,N'-Bis-(4-hexyl-phenyl)-guanidine | Drug Info | [26] | |||
| 60 | N,N'-Bis-(4-isopropyl-phenyl)-guanidine | Drug Info | [26] | |||
| 61 | N,N'-Bis-(4-sec-butyl-phenyl)-guanidine | Drug Info | [26] | |||
| 62 | N-(2-methoxybenzyl)cinnamamidine | Drug Info | [41] | |||
| 63 | Nle-Pro-Glu | Drug Info | [24] | |||
| 64 | Phe-Pro-Glu | Drug Info | [24] | |||
| 65 | PHENCYCLIDINE | Drug Info | [43] | |||
| 66 | RPR-118723 | Drug Info | [22] | |||
| 67 | TRANSTORINE | Drug Info | [30] | |||
| Agonist | [+] 5 Agonist drugs | + | ||||
| 1 | (+)-HA966 | Drug Info | [19] | |||
| 2 | (RS)-(tetrazol-5-yl)glycine | Drug Info | [19] | |||
| 3 | D-aspartic acid | Drug Info | [19] | |||
| 4 | homoquinolinic acid | Drug Info | [19] | |||
| 5 | L-aspartic acid | Drug Info | [19] | |||
| Blocker (channel blocker) | [+] 2 Blocker (channel blocker) drugs | + | ||||
| 1 | N1-dansyl-spermine | Drug Info | [19] | |||
| 2 | [3H]dizocilpine | Drug Info | [19] | |||
| Modulator (allosteric modulator) | [+] 1 Modulator (allosteric modulator) drugs | + | ||||
| 1 | TCN-201 | Drug Info | [44] | |||
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| Target Regulators | Top | |||||
|---|---|---|---|---|---|---|
| Target-interacting Proteins | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78. | |||||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 727). | |||||
| REF 3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016784. | |||||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4264). | |||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002155) | |||||
| REF 6 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2403). | |||||
| REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000713) | |||||
| REF 8 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4239). | |||||
| REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001828) | |||||
| REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006620) | |||||
| REF 11 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003218) | |||||
| REF 12 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4240). | |||||
| REF 13 | Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther. 1996 Nov;279(2):492-501. | |||||
| REF 14 | L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. Psychopharmacology (Berl). 1999 Apr;143(3):235-43. | |||||
| REF 15 | Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65. | |||||
| REF 16 | 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7. | |||||
| REF 17 | Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9. | |||||
| REF 18 | Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). | |||||
| REF 19 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). | |||||
| REF 20 | Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. | |||||
| REF 21 | CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2... J Med Chem. 2005 Feb 24;48(4):995-1018. | |||||
| REF 22 | Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81. | |||||
| REF 23 | Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7. | |||||
| REF 24 | New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. | |||||
| REF 25 | Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. | |||||
| REF 26 | Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. | |||||
| REF 27 | 2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents. J Med Chem. 1990 Oct;33(10):2772-7. | |||||
| REF 28 | Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. | |||||
| REF 29 | 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). | |||||
| REF 30 | 3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6. | |||||
| REF 31 | Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. | |||||
| REF 32 | 3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9. | |||||
| REF 33 | 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86. | |||||
| REF 34 | Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26. | |||||
| REF 35 | Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobut... J Med Chem. 1992 Dec 11;35(25):4720-6. | |||||
| REF 36 | Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41. | |||||
| REF 37 | Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors. J Biol Chem. 2007 Dec 21;282(51):36905-13. | |||||
| REF 38 | Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antago... J Med Chem. 1991 Apr;34(4):1243-52. | |||||
| REF 39 | The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400. | |||||
| REF 40 | Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther. 1999 Sep;290(3):1034-40. | |||||
| REF 41 | Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5439-41. | |||||
| REF 42 | Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci. 2006 Feb 1;26(5):1331-3. | |||||
| REF 43 | Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopro... J Med Chem. 1996 Nov 22;39(24):4844-52. | |||||
| REF 44 | Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. J Neurosci. 2012 May 2;32(18):6197-208. | |||||
| REF 45 | The binding of [3H]thienyl cyclohexylpiperidine ([3H]TCP) to the NMDA-phencyclidine receptor complex. Neuropharmacology. 1989 Jan;28(1):1-7. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.